🔎 Trials Near Me

Почетна › Akutna mijeloidna leukemija › Тексас

Kliničke studije za Akutna mijeloidna leukemija u državi Тексас

97 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u državi Тексас.

Gradovi u državi Тексас

Zvanični tekst studije (na engleskom)

CD70.CAR for AML and Other CD70+ Leukemias

  • Texas Children's Hospital, Houston
  • The Methodist Hospital, Houston
Тражи се учесникФаза 1
До 75 година · Оба пола · Ажурирано 13. 11. 2026. · NCT06345027

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

  • UT MD Anderson, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07549464

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04774393

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст од 18 до 65 · Оба пола · Ажурирано 12. 11. 2026. · NCT02115295

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Texas Oncology-Austin Midtown, Austin
  • Texas Oncology-Presbyterian Cancer Center, Dallas
  • University of Texas, Houston
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT03589729

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Baylor University Medical Center, Dallas
  • Houston Methodist Cancer Center, Houston
  • MD Anderson Cancer Center, Houston
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222

Personalized NK Cell Therapy in CBT

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст од 15 до 80 · Оба пола · Ажурирано 2. 11. 2026. · NCT02727803

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT03214562

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • Baylor Charles A. Sammons Cancer Center, Dallas
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 30. 10. 2026. · NCT05429632

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

  • MD Anderson Cancer Center, Houston
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 30. 10. 2026. · NCT06906380

Study of REM-422 in Patients With AML or Higher Risk MDS

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06297941

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Texas Children's Hospital, Houston
Тражи се учесникОпсервациона студија
Узраст од 0 до 38 · Оба пола · Ажурирано 29. 10. 2026. · NCT06131801

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  • MD Anderson, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05143996

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  • Research Site, Houston
Тражи се учесникФаза 1/2
Узраст 16 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07155226

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06969430

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Тражи се учесникФаза 1
До 21 година · Оба пола · Ажурирано 23. 10. 2026. · NCT07012044

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • UT Southwestern/Simmons Cancer Center, Dallas
  • Cook Children's Medical Center, Fort Worth
Тражи се учесникФаза 1
Узраст од 1 до 30 · Оба пола · Ажурирано 22. 10. 2026. · NCT06177067

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  • The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07581002

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст од 18 до 85 · Оба пола · Ажурирано 21. 10. 2026. · NCT06834282

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Houston
Тражи се учесникФаза 3
Узраст 12 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT07211958

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06533761

A Study of Revumenib and Mezigdomide in People With Leukemia

  • MD Anderson Cancer Center (Data Collection Only), Houston
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT07356154

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

  • University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06846606

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

  • M.D. Anderson Cancer Center, Department of Leukemia, Houston
Тражи се учесникФаза 1Здраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT05986240

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT02390635

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT05010772

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06616636

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

  • Houston Methodist Neal Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07060001

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • University of Texas Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04140487

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

  • The University of Texas M. D. Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06811233

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Children's Medical Center Dallas /ID# 275930, Dallas
Тражи се учесникФаза 1
6 Months – 17 Years · Оба пола · Ажурирано 5. 10. 2026. · NCT07306832

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 50 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT03586609

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст од 12 до 78 · Оба пола · Ажурирано 29. 9. 2026. · NCT03802695

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT03629171

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.